Share

Corporate Documents

Allergy Therapeutics plc - Articles of Association 20 November 2008

Click here to download the Articles of Association 20 November 2008

Allergy Therapeutics plc - AIM Admission Document is published here in compliance with Rule 26 of the AIM Rules for Companies October 2004

This admission document, which is not a prospectus, does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for Ordinary Shares in any jurisdiction in which such offer or solicitation is unlawful and, in particular, is not intended for distribution in or into the United States, Canada, Australia, Ireland, South Africa or Japan. The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933 (the “Securities Act”) as amended, or any state securities laws and, unless so registered, may not be offered or sold except pursuant to an exemption from, or in a transaction not subject to the registration requirements of, the Securities Act and applicable state securities laws. Nor have the securities been registered under the applicable securities laws of Canada, Australia, Ireland, South Africa or Japan. The distribution of this document in other jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdiction.

Click here to download the Admission document 6 October 2004

Allergy Therapeutics plc - Proposed Placing, Subscription and Offer June 2009

The document below, which is not a prospectus, does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for Ordinary Shares in any jurisdiction in which such offer or solicitation is unlawful and, in particular, is not intended for distribution in or into the United States, Canada, Australia, Ireland, South Africa or Japan. The Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933 (the “Securities Act”) as amended, or any state securities laws and, unless so registered, may not be offered or sold except pursuant to an exemption from, or in a transaction not subject to the registration requirements of, the Securities Act and applicable state securities laws. Nor have the securities been registered under the applicable securities laws of Canada, Australia, Ireland, South Africa or Japan. The distribution of this document in other jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdiction.

Click here to download the Circular June 2009.

Allergy Therapeutics plc - Waiver of Rule 9 of Takeover Code, Proposed Placing and Subscription and Offer Circular March 2012

The document below does not constitute an offer of transferable securities to the public within the meaning of section 102B of Financial Services and Markets Act 2000 (as amended) (“FSMA”). The issue of the Placing Shares, Offer Shares and Subscription Shares will not constitute an offer to the public requiring an approved prospectus under section 85 of FSMA and accordingly this document does not constitute a prospectus for those purposes. This document is not a prospectus for the purposes of the Prospectus Rules. Accordingly, this document has not been, and will not be, reviewed or approved by the Financial Services Authority of the United Kingdom (“FSA’’), pursuant to sections 85 and 87 of FSMA, London Stock Exchange plc or any other authority or regulatory body.  The distribution of this document, and/or the Application Form, in jurisdictions other than the UK may be restricted by law and therefore persons into whose possession this document and/or accompanying documents come should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws or regulations of such jurisdictions.

Click here to download the Circular March 2012   

Allergy Therapeutics plc – Loan Note Instrument 30 March 2012.

Click here to download the Loan Note Instrument 30 March 2012

Allergy Therapeutics plc - Proposed Placing and Notice of General Meeting Circular 10 March 2015.

Placing to raise net proceeds of approximately £20 million to be used to fund the clinical development of Pollinex Quattro Grass through to FDA regulatory approval.

Click here to download the Proposed Placing and Notice of General Meeting Circular 10 March 2015

Share